ACTRN12622001026718
Recruiting
未知
Evaluating the effectiveness of a comprehensive lifestyle therapy program versus psychological care for managing mood disorders: The HARMON-E Trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Major depressive disorder
- Sponsor
- Deakin University
- Enrollment
- 378
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Are 18 years or older
- •2\.Have experienced a major depressive episode in the past two years
- •3\.Score equal to or greater than 20 on the MADRS
- •4\.Have capacity to provided informed consent and converse in English (or attend the program/assessments with a carer/companion who does)
- •5\.Are suited to participation and engagement in a structured group\-based lifestyle or psychotherapy program for 8 weeks
- •6\.Have basic computer and internet literacy
Exclusion Criteria
- •1\.Endorse all the following lifestyle behaviours:
- •a.Non\-smoker
- •Identified by answering ‘no’ to pre\-screening question: Do you regularly smoke, chew or consume tobacco (current not past use)?
- •b.Report an optimal diet
- •Meeting the Australian Dietary Guidelines for fruit and vegetable intake
- •c.Sleep quality
- •High sleep quality Identified as having 7\-9 hours of sleep most nights of the week
- •d.Physical activity
- •Identified by exceeding the national guidelines for physical activity in Australia
- •e.Alcohol \& drug use
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Investigation the effectiveness of comprehensive nursing care on uremic pruritus, sleep quality and dialysis adequacy in patients undergoing hemodialysis treatmentPatients treated with hemodialysis.Chronic kidney disease, stage 5N18.5IRCT20231021059797N1Zabol University of Medical Sciences70
Recruiting
Not Applicable
Evaluating the effectiveness of a comprehensive chronic disease management service focused on primary care for hypertension and diabetes patients in real-world settings: a community-based clinical studyKCT0007910The Catholic University of Korea950
Active, not recruiting
Not Applicable
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2006-001449-33-SESchering Plough Institute, A Division of Schering Corporation600
Active, not recruiting
Not Applicable
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCEEUCTR2006-001449-33-CZSchering-Plough Research Institute, A Division of Schering Corporation600
Active, not recruiting
Phase 1
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). Estudio de la eficacia, seguridad y calidad de vida (cdv) en pacientes con urticaria crónica idiopática tratados con aerius comprimidos (5, 10 ó 20 mg) una vez al día - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1 Level: LLT Classification code 10021247 Term: Idiopathic urticariaEUCTR2006-001449-33-ESIntegrated Therapeutics Group Incorporated (ITGI)600